IRB #

IRB00008710

Title

An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy with MSC1936369B and SAR245409 in Subjects with Locally Advanced or Metastatic Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

Determine the Maximum Tolerated Dose (MTD) of the study drug combination (MSC1936369B and SAR245409)

Medical Condition(s)

Locally advanced or metastatic solid tumors

Eligibility Criteria

1. Advanced solid tumor for which there is no approved therapy
2. Measurable or evaluable disease
3. Aged 18 or older

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression, unacceptable side effects, investigator's decision, or withdrawal by subject.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

EMD Serono, Inc.

Recruitment End

06/30/2013

Compensation Provided

No